- Home
- COO vs INCY Comparison
COO vs INCY Comparison
Compare COO & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COO
- INCY
- Stock Information
- Founded
- COO 1980
- INCY 1991
- Country
- COO United States
- INCY United States
- Employees
- COO N/A
- INCY N/A
- Industry
- COO Ophthalmic Goods
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- COO Health Care
- INCY Health Care
- Exchange
- COO Nasdaq
- INCY Nasdaq
- Market Cap
- COO 15.6B
- INCY 13.4B
- IPO Year
- COO N/A
- INCY 1993
- Fundamental
- Price
- COO $80.89
- INCY $59.16
- Analyst Decision
- COO Buy
- INCY Hold
- Analyst Count
- COO 9
- INCY 20
- Target Price
- COO $110.25
- INCY $73.81
- AVG Volume (30 Days)
- COO 2.0M
- INCY 2.0M
- Earning Date
- COO 05-29-2025
- INCY 04-29-2025
- Dividend Yield
- COO N/A
- INCY N/A
- EPS Growth
- COO 41.73
- INCY N/A
- EPS
- COO 2.07
- INCY 0.15
- Revenue
- COO $3,928,500,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- COO $6.77
- INCY $12.21
- Revenue Next Year
- COO $6.56
- INCY $9.20
- P/E Ratio
- COO $39.37
- INCY $392.73
- Revenue Growth
- COO 7.15
- INCY 14.76
- 52 Week Low
- COO $69.81
- INCY $50.35
- 52 Week High
- COO $112.38
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- COO 51.25
- INCY 46.02
- Support Level
- COO $77.59
- INCY $57.29
- Resistance Level
- COO $82.84
- INCY $59.95
- Average True Range (ATR)
- COO 3.10
- INCY 2.57
- MACD
- COO 0.85
- INCY 0.44
- Stochastic Oscillator
- COO 85.03
- INCY 70.80
About COO The Cooper Companies Inc.
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.